Antimicrobial compounds; Nano-containers; Triggered drug release; Molecular Recognition; DNA-templated synthesis; Signal transduction
Gagnon Jacinthe, Fromm Katharina M. (2015), Toxicity and Protective Effects of Cerium Oxide Nanoparticles (Nanoceria) Depending on Their Preparation Method, Particle Size, Cell Type, and Exposure Route, in Eur. J. Inorg. Chem.
, 27, 4510.
Eckhardt Sonja, Brunetto P. S., Gagnon Jacinthe, Priebe Magdalena, Giese Bernd, Fromm Katharina M. (2013), Nanobio Silver – Its Interactions with Peptides & Bacteria, and Its Uses in Medicine, in Chem. Rev.
, 113, 4708-4754.
Gagnon Jacinthe, Weber Pierric, Fromm Katharina M. (2011), Nanoencapsulation of Anti-Microbial Drugs, in Europ. Cells & Materials
, ecm journal, ecm journal.
Priebe Magdalena, Fromm Katharina M. (2011), One-pot synthesis and catalytic properties of encapsulated silver nanoparticles in silica nanocontainers, in Europ. Cells & Materials
, Wiley, Wiley.
Gagnon Jacinthe, Clift Martin J. D., Vanhecke D., Kuhn D. A., Weber P., Petri-Fink Alke, Rothen-Rutishauser B., Fromm Katharina M., Integrating Silver Compounds and Nanoparticles into Ceria Nanocontainers for Antimicrobial Applications, in Journal of Materials Chemistry B
Priebe Magdalena, Fromm Katharina M., Nanorattles or Yolk-Shell Nanoparticles - What they are, How are they Made, and What Are They Good For?, in Chem. Eur. J.
The number of patients requiring joint replacement or internal fixation devices is steadily increasing. E.g. in the U.S., 600’000 joint prostheses and 2 million fracture fixation devices are implanted every year. Infections of these implants can become a very serious problem, the infection rate being ca. 1-2% for hip or knee implants, and up to almost 20% for pacemakers. These infections frequently occur perioperatively by bacterial contamination of the surgical site, which form biofilms, allowing bacteria to resist antimicrobial agents and immune responses. We therefore propose to develop new materials which i) release drugs only when and where they are needed, ii) dramatically reduce the percentage of implant infection, iii) decrease the trend of resistance build-up by bacteria, iv) reduce health costs, v) improve the quality of life for patients, and vi) yield new products to be produced and sold by manufacturers of implants and fracture fixation devices. In two work packages, we will i) develop a concept of drug-filled nanocontainers attached to a (coated) implant surface and ii) bacterial sensors which shall trigger increased drug release from these nanocapsules.